Lymphoplasmacytic Lymphoma

Following multidisciplinary consultation, the patient was treated with the bendamustine plus rituximab (BR) regimen. Second, for WM patients with renal AL amyloidosis, choosing BR regimen as the first-line treatment is reasonable. However, during the treatment process, it is essential to closely monitor and actively prevent the adverse effects of this regimen, particularly severe infections which may have fatal consequences.

P2, N=33, Active, not recruiting, University of Washington | Trial completion date: Jan 2031 --> Jan 2028

Other targeted approaches, including BCL2 and proteasome inhibition, offer additional options for personalized therapy. Ongoing integration of molecular and microenvironmental data is expected to enhance risk stratification and support the development of more effective, tailored treatment strategies.

P1, N=9, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed

P1, N=30, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2026 --> May 2027

P2, N=300, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2027

Our results highlight a clinically relevant genotype-phenotype discordance and support the integration of molecular hallmarks into diagnostic algorithms to better reflect the biological spectrum of cold agglutinin-associated disorders. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

P1/2, N=190, Active, not recruiting, ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027

The patient received six cycles of bendamustine and rituximab (BR), leading to a reduction in hepatic lesions and IgM levels, though treatment was complicated by persistent cytopenias. Comprehensive histopathological and molecular evaluation is critical for accurate diagnosis and appropriate therapy. Our report expands the spectrum of extramedullary WM and highlights the potential for favorable response to BR despite unusual presentation.

P1, N=85, Recruiting, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | N=50 --> 85

After six cycles of azacitidine, she achieved remission of MDS but rapidly progressed to AML and ultimately died. This case provides a key clinical lesson: persistent cytopenias during ibrutinib therapy were attributable to MDS progression rather than SWM, underscoring the importance of re-evaluation. Furthermore, it completely documents clonal evolution from 2.5% blasts (MDS with low blasts) to 6% blasts (MDS with increased blasts-1) and ultimately to AML (66% blasts), and it introduces the emergence of an FLT3-ITD mutation that rapidly drove the disease into AML even after the patient had achieved MDS remission. We also review the rare coexistence of WM and MDS/AML, and MGUS with MDS.